Format

Send to

Choose Destination
Euro Surveill. 2019 Jan;24(4). doi: 10.2807/1560-7917.ES.2019.24.4.1900055.

Interim estimates of 2018/19 vaccine effectiveness against influenza A(H1N1)pdm09, Canada, January 2019.

Author information

1
University of British Columbia, Vancouver, Canada.
2
British Columbia Centre for Disease Control, Vancouver, Canada.
3
University of Toronto, Toronto, Canada.
4
Public Health Ontario, Toronto, Canada.
5
University of Calgary, Calgary, Canada.
6
University of Alberta, Edmonton, Canada.
7
Provincial Laboratory for Public Health, Edmonton, Canada.
8
Institut National de Santé Publique du Québec, Quebec City, Canada.
9
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
10
Centre Hospitalier Universitaire de Québec, Quebec City, Canada.
11
Laval University, Quebec City, Canada.

Abstract

Using a test-negative design, the Canadian Sentinel Practitioner Surveillance Network assessed interim 2018/19 vaccine effectiveness (VE) against predominant influenza A(H1N1)pdm09 viruses. Adjusted VE was 72% (95% confidence interval: 60 to 81) against medically attended, laboratory-confirmed influenza A(H1N1)pdm09 illness. This substantial vaccine protection was observed in all age groups, notably young children who appeared to be disproportionately affected. Sequence analysis identified heterogeneity in emerging clade 6B.1 viruses but no dominant drift variant.

KEYWORDS:

Canada; ILI; epidemiology; genomics; immunisation; influenza; influenza virus; influenza-like illness; laboratory; vaccine effectiveness; vaccine-preventable diseases; vaccines; viral infections

Supplemental Content

Full text links

Icon for Ingenta plc Icon for PubMed Central
Loading ...
Support Center